176 related articles for article (PubMed ID: 30208284)
1. Bepotastine besilate for the treatment of perennial allergic rhinitis.
Carrillo-Martin I; Gonzalez-Estrada A; Dimov V
Expert Opin Pharmacother; 2018 Oct; 19(15):1727-1730. PubMed ID: 30208284
[TBL] [Abstract][Full Text] [Related]
2. Bepotastine besilate for the treatment of pruritus.
Bielory L; Duttachoudhury S; McMunn A
Expert Opin Pharmacother; 2013 Dec; 14(18):2553-69. PubMed ID: 24191914
[TBL] [Abstract][Full Text] [Related]
3. Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis.
Okubo K; Ichimura M; Koyama T; Susuta Y; Izaki H
Expert Opin Pharmacother; 2015; 16(16):2395-408. PubMed ID: 26364765
[TBL] [Abstract][Full Text] [Related]
4. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
5. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
6. Oral bepotastine: in allergic disorders.
Lyseng-Williamson KA
Drugs; 2010 Aug; 70(12):1579-91. PubMed ID: 20687621
[TBL] [Abstract][Full Text] [Related]
7. Ebastine in allergic rhinitis and chronic idiopathic urticaria.
Sastre J
Allergy; 2008 Dec; 63 Suppl 89():1-20. PubMed ID: 19032340
[TBL] [Abstract][Full Text] [Related]
8. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate.
Williams JI; Gow JA; Klier SM; McCue SL; Salapatek AM; McNamara TR
Curr Med Res Opin; 2010 Oct; 26(10):2329-38. PubMed ID: 20735291
[TBL] [Abstract][Full Text] [Related]
9. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
[TBL] [Abstract][Full Text] [Related]
10. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.
Dechant KL; Goa KL
Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851
[TBL] [Abstract][Full Text] [Related]
11. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Macejko TT; Bergmann MT; Williams JI; Gow JA; Gomes PJ; McNamara TR; Abelson MB;
Am J Ophthalmol; 2010 Jul; 150(1):122-127.e5. PubMed ID: 20488431
[TBL] [Abstract][Full Text] [Related]
12. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin.
Tashiro M; Duan X; Kato M; Miyake M; Watanuki S; Ishikawa Y; Funaki Y; Iwata R; Itoh M; Yanai K
Br J Clin Pharmacol; 2008 Jun; 65(6):811-21. PubMed ID: 18410464
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
Ayyappanavar S; Sridhar S; Kumar K; Jayanthi CR; Gangasagara SB; Rathod BLS; Preethi B; Mittal P
Indian J Ophthalmol; 2021 Feb; 69(2):257-261. PubMed ID: 33463568
[TBL] [Abstract][Full Text] [Related]
14. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.
Torkildsen GL; Williams JI; Gow JA; Gomes PJ; Abelson MB; McNamara TR;
Ann Allergy Asthma Immunol; 2010 Jul; 105(1):57-64. PubMed ID: 20642205
[TBL] [Abstract][Full Text] [Related]
15. [Effect of betotastine besilate (TAU-284), a novel anti-allergic agent, on experimental allergic rhinitis].
Murata T; Matsumoto Y; Suzuki T; Naito K; Takata I; Tsuzurahara K
Arerugi; 1997 Jul; 46(7):576-84. PubMed ID: 9301130
[TBL] [Abstract][Full Text] [Related]
16. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
Meier EJ; Torkildsen GL; Gow JA; McNamara TR; Gomes PJ; Williams JI;
Allergy Asthma Proc; 2012; 33(3):265-74. PubMed ID: 22991696
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.
Carr WW; Nayak AS; Ratner PH; Gow JA; McNamara TR; Williams JI;
Allergy Asthma Proc; 2013; 34(3):247-54. PubMed ID: 23484763
[TBL] [Abstract][Full Text] [Related]
18. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.
Bousquet J; Ansótegui I; Canonica GW; Zuberbier T; Baena-Cagnani CE; Bachert C; Cruz AA; González SN; Kuna P; Morais-Almeida M; Mullol J; Ryan DP; Sánchez-Borges M; Valiente R; Church MK
Curr Med Res Opin; 2012 Jan; 28(1):131-9. PubMed ID: 22149770
[TBL] [Abstract][Full Text] [Related]
19. Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis.
Bartra J; Mullol J; Montoro J; Jáuregui I; del Cuvillos A; Dávila I; Ferrer M; Sastre J; Valero A
J Investig Allergol Clin Immunol; 2011; 21 Suppl 3():24-33. PubMed ID: 22185047
[TBL] [Abstract][Full Text] [Related]
20. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.
Wolthers OD
Biomed Res Int; 2013; 2013():626837. PubMed ID: 23956994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
